有静脉血栓栓塞史的妊娠及产后妇女中中等剂量与低剂量低分子肝素比较(Highlow研究):一项开放标签、多中心、随机对照试验
Highlow研究为开放标签、多中心、随机对照试验,纳入70家医院、9个国家、有客观确诊静脉血栓栓塞史且孕龄≤14周的妊娠妇女1110例,随机分配至体重调整中等剂量或固定低剂量低分子肝素皮下注射每日一次,直至产后6周。主要疗效终点静脉血栓栓塞在中等剂量组11/555(2%)vs 低剂量组16/555(3%)(RR 0.69,95%CI 0.32-1.47;p=0.33),差异未达统计学显著。主要安全终点大出血在中等剂量组23/520(4%)vs 低剂量组20/525(4%)(RR 1.16,95%CI 0.65-2.09)。作者认为,妊娠期低剂量低分子肝素是预防妊娠相关复发性静脉血栓栓塞的适宜剂量。
要点
- 有静脉血栓栓塞史的妊娠妇女,体重调整中等剂量低分子肝素与固定低剂量相比,静脉血栓栓塞复发率2% vs 3%(RR 0.69,95%CI 0.32-1.47;p=0.33),未达统计学显著。
- 产前静脉血栓栓塞事件中等剂量组5例(1%)vs 低剂量组5例(1%),产后分别为6例(1%)vs 11例(2%)。
- 治疗期间大出血在中等剂量组23/520(4%)vs 低剂量组20/525(4%)(RR 1.16,95%CI 0.65-2.09)。
- 作者结论:妊娠期低剂量低分子肝素是预防妊娠相关复发性静脉血栓栓塞的适宜剂量。
适用人群与场景
- 年龄18岁及以上、有客观确诊静脉血栓栓塞史、孕龄≤14周的妊娠妇女,来自70家医院、9个国家(荷兰、法国、爱尔兰、比利时、挪威、丹麦、加拿大、美国、俄罗斯)。
诊断标准与关键阈值
- 入组标准:年龄≥18岁,有客观确诊的静脉血栓栓塞史,孕龄≤14周。
- 随机分组在孕龄14周前进行,按中心分层,1:1分配至体重调整中等剂量或固定低剂量低分子肝素皮下注射每日一次,直至产后6周。
处置流程与药物剂量
- 体重调整中等剂量低分子肝素皮下注射每日一次,直至产后6周。
- 固定低剂量低分子肝素皮下注射每日一次,直至产后6周。
红旗征与不能漏的情况
- 主要安全终点大出血包括产前、产后早期(分娩后24小时内)和产后晚期(分娩后24小时至产后6周)大出血。
研究设计与关键结果
- 开放标签、多中心、随机对照试验(Highlow),纳入70家医院、9个国家,筛查1339例妊娠妇女,随机分配1110例至体重调整中等剂量组(n=555)或固定低剂量组(n=555)(ITT人群)。
- 主要疗效终点静脉血栓栓塞(深静脉血栓、肺栓塞或异常部位静脉血栓,由独立中心裁定委员会确定)在中等剂量组11/555(2%)vs 低剂量组16/555(3%)(RR 0.69,95%CI 0.32-1.47;p=0.33)。
- 产前静脉血栓栓塞:中等剂量组5例(1%)vs 低剂量组5例(1%);产后:中等剂量组6例(1%)vs 低剂量组11例(2%)。
- 主要安全终点治疗期间大出血在安全性人群(N=1045)中:中等剂量组23/520(4%)vs 低剂量组20/525(4%)(RR 1.16,95%CI 0.65-2.09)。
证据类型、等级与局限
- 证据类型:开放标签、多中心、随机对照试验(Highlow)。
- 研究注册号:ClinicalTrials.gov,NCT01828697。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,妊娠期低剂量低分子肝素是预防妊娠相关复发性静脉血栓栓塞的适宜剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pregnancy-related venous thromboembolism is a leading cause of maternal morbidity and mortality, and thromboprophylaxis is indicated in pregnant and post-partum women with a history of venous thromboembolism. The optimal dose of low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy and the post-partum period is uncertain.
METHODS: In this open-label, randomised, controlled trial (Highlow), pregnant women with a history of venous thromboembolism were recruited from 70 hospitals in nine countries (the Netherlands, France, Ireland, Belgium, Norway, Denmark, Canada, the USA, and Russia). Women were eligible if they were aged 18 years or older with a history of objectively confirmed venous thromboembolism, and with a gestational age of 14 weeks or less. Eligible women were randomly assigned (1:1), before 14 weeks of gestational age, using a web-based system and permuted block randomisation (block size of six), stratified by centre, to either weight-adjusted intermediate-dose or fixed low-dose low-molecular-weight heparin subcutaneously once daily until 6 weeks post partum. The primary efficacy outcome was objectively confirmed venous thromboembolism (ie, deep-vein thrombosis, pulmonary embolism, or unusual site venous thrombosis), as determined by an independent central adjudication committee, in the intention-to-treat (ITT) population (ie, all women randomly assigned to treatment). The primary safety outcome was major bleeding which included antepartum, early post-partum (within 24 h after delivery), and late post-partum major bleeding (24 h or longer after delivery until 6 weeks post partum), assessed in all women who received at least one dose of assigned treatment and had a known end of treatment date. This study is registered with ClinicalTrials.gov, NCT01828697, and is now complete.
FINDINGS: Between April 24, 2013, and Oct 31, 2020, 1339 pregnant women were screened for eligibility, of whom 1110 were randomly assigned to weight-adjusted intermediate-dose (n=555) or fixed low-dose (n=555) low-molecular-weight heparin (ITT population). Venous thromboembolism occurred in 11 (2%) of 555 women in the weight-adjusted intermediate-dose group and in 16 (3%) of 555 in the fixed low-dose group (relative risk [RR] 0·69 [95% CI 0·32-1·47]; p=0·33). Venous thromboembolism occurred antepartum in five (1%) women in the intermediate-dose group and in five (1%) women in the low-dose group, and post partum in six (1%) women and 11 (2%) women. On-treatment major bleeding in the safety population (N=1045) occurred in 23 (4%) of 520 women in the intermediate-dose group and in 20 (4%) of 525 in the low-dose group (RR 1·16 [95% CI 0·65-2·09]).
INTERPRETATION: In women with a history of venous thromboembolism, weight-adjusted intermediate-dose low-molecular-weight heparin during the combined antepartum and post-partum periods was not associated with a lower risk of recurrence than fixed low-dose low-molecular-weight heparin. These results indicate that low-dose low-molecular-weight heparin for thromboprophylaxis during pregnancy is the appropriate dose for the prevention of pregnancy-related recurrent venous thromboembolism.
FUNDING: French Ministry of Health, Health Research Board Ireland, GSK/Aspen, and Pfizer.
参考来源
- Bistervels IM, Buchmüller A, Wiegers HMG, et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet. 2022. PMID: 36354038. doi:10.1016/S0140-6736(22)02128-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。